<html><head><script id="decision-support-view" type="application/json">{
  "dsViewId": "ATRIA_bleeding_risk.v1",
  "language": {
    "originalLanguage": {
      "terminologyId": {
        "name": "ISO_639-1",
        "value": "ISO_639-1"
      },
      "codeString": "en"
    }
  },
  "decisionSupportViewDefinitions": {
    "sv": {
      "name": "ATRIA Bleeding Risk Score",
      "description": "Uppskatta risk för warfarin-associerad blödning hos patienter med förmaksflimmer"
    },
    "en": {
      "name": "ATRIA Bleeding Risk Score",
      "description": "Predict warfarin-associated hemorrhage in patients with atrial fibrillation"
    }
  },
  "resourceDescription": {
    "originalAuthor": {
      "date": "2017-02-13",
      "name": "Eneimi Allwell-Brown",
      "organisation": "Cambio Healthcare Systems"
    },
    "otherContributors": [
      "Dennis Forslund, Cambio Healthcare Systems"
    ],
    "details": {
      "sv": {
        "purpose": "Att hos patienter med förmaksflimmer uppskatta risken för warfarin-associerad blödning.",
        "keywords": [
          "antikoagulantia",
          "förmaksflimmer",
          "warfarin",
          "blödning",
          "blödningsrisk",
          "kardiologi",
          "waran"
        ],
        "use": "Att registrera data i enlighet med Anticoagulation and Risk Factors in Atrial Fibrillation Score (ATRIA). Instrumentet baseras på följande faktorer:\n\n- Anemi\n- Svår njursjukdom (eGFR \u003c30 ml/min alternativ dialys)\n- Ålder ≥75 år\n- Tidigare blödning\n- Hypertoni\n\nResultatet uppgår till maximalt 10p, och tolkas med avseende på risk för warfarin-associerad blödning enligt:\n\u003c4p - låg risk (0,8%)\n4p - mellanrisk (2,6%)\n\u003e4p - hög risk (5,8%)\n\nUtfallet definieras som blödning med dödlig utgång, behov av minst två enheter blodtransfusion eller blödning i kritisk anatomisk lokal såsom intrakraniellt eller retroperitonealt.\n\nInstrumentet kan användas som stöd för beslut kring huruvida behandling med warfarin är lämplig samt utvärdera behandling med antikoagulantia hos patienter med förmaksflimmer.",
        "misuse": "Endast avsedd för patienter med förmaksflimmer.",
        "copyright": "Cambio Healthcare Systems"
      },
      "en": {
        "purpose": "Determine risk of warfarin-associated hemorrhage in individuals with atrial fibrillation.",
        "keywords": [
          "anticoagulation",
          "atrial fibrillation",
          "warfarin",
          "major hemorrhage",
          "hemorrhage risk",
          "cardiology"
        ],
        "use": "To record data for ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) bleeding risk score and associated variables.\n\nPoints are assigned based on the presence of the following 5 easily assessable clinical variables: \n - anemia \u003d 3 points; \n - severe renal disease (estimated glomerular filtration rate \u003c30 ml/min or on dialysis) \u003d 3 points; \n - age ≥75 years \u003d 2 points; \n - prior bleeding \u003d 1 point; \n - hypertension \u003d 1 point.\n\nMinimum score \u003d 0 and maximum score \u003d 10.\nIndividuals with total score \u003c4 are at low risk (0.8%) of warfarin-associated hemorrhage, score of 4 is intermediate risk (2.6%) and score \u003e4 is classified as high risk (5.8%).\n\nThe score is used in the determination of whether to commence warfarin anticoagulation, as well as during re-evaluation of anticoagulation therapy, in patients with atrial fibrillation. ",
        "misuse": "Do not use if the patient does not have atrial fibrillation.",
        "copyright": "Cambio Healthcare Systems"
      }
    },
    "otherDetails": {
      "references": "Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. Journal of the American College of Cardiology. 2011 Jul 19;58(4):395-401.\n\nApostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. Journal of the American College of Cardiology. 2012 Aug 28;60(9):861-7.\n\nRoldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. CHEST Journal. 2013 Jan 1;143(1):179-84."
    }
  },
  "alertGuideIds": [],
  "executionGuideIds": [
    "ATRIA_bleeding_risk_score_Assessment.v1",
    "ATRIA_bleeding_risk_score_Calculation.v1"
  ],
  "alertBindings": {},
  "termDefinitions": {
    "sv": {
      "id": "sv",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "Referenser"
        }
      }
    },
    "en": {
      "id": "en",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "References"
        }
      }
    }
  }
}</script></head><body></body></html>